Itracat 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. The capsule formulation ensures optimal bioavailability when taken with food, facilitating effective systemic absorption. Itracat 100 is typically administered orally, with dosing regimens tailored according to the severity and type of infection, patient response, and clinical judgment. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used cautiously in individuals with hepatic impairment due to potential hepatotoxicity. Concomitant use with certain drugs metabolized by CYP3A4 may result in significant drug interactions. Regular monitoring of liver function tests and clinical response is recommended during therapy. Itracat 100 Capsule provides an effective therapeutic option for managing difficult-to-treat fungal infections under medical supervision.